Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA Exploring new territories of oncology and immunology in search of therapeutic approaches able to save lives Very Serious About Incurable Diseases Breaking the impasse with “sole-in-class" drug candidates Latest news Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany September 8, 2021 Diaccurate introduces its world-leading Scientific Advisory Board July 8, 2021 Diaccurate acquires Biokinesis to create a sole-in-class biotech player in oncology and immunotherapy January 12, 2021 See all press releases Upcoming events AACR Annual Meeting 2022 April 8, 2022 - April 13, 2022 See all upcoming events
Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany September 8, 2021
Diaccurate acquires Biokinesis to create a sole-in-class biotech player in oncology and immunotherapy January 12, 2021
